Related Experiment Video

Updated: Sep 4, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

A systematic pan-cancer analysis identifies RIOK3 as an immunological and prognostic biomarker

Jian Li1, Ruili Sun2, Lixiang He1

  • 1Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University Xinxiang 453003, Henan, China.

American Journal of Translational Research
|July 15, 2022
PubMed
Abstract

Insights

RIOK3 is a key factor in cancer development and progression. This study reveals RIOK3 as a potential prognostic and immune biomarker across various human malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background:

  • RIOK3 (RIO kinase 3) plays a crucial role in various cancers, but its comprehensive role in human tumors remains unclear.
  • Understanding RIOK3's molecular mechanisms in carcinogenesis is essential for developing targeted therapies.

Purpose of the Study:

  • To comprehensively evaluate the role of RIOK3 in human cancers.
  • To clarify the molecular mechanisms of RIOK3 in carcinogenesis from multiple perspectives.
  • To investigate RIOK3 as a potential biomarker for cancer prognosis and immunotherapy.

Main Methods:

  • Utilized TCGA, GTEx, and GEO datasets for analysis across 33 cancer types.
  • Employed bioinformatics tools to assess RIOK3 expression, mutations, and correlations.
  • Performed univariate survival analysis and investigated immune cell infiltration and immune checkpoint markers.

Main Results:

  • RIOK3 expression is dysregulated in tumors compared to normal tissues.
  • RIOK3 levels correlate with mismatch repair (MMR) gene mutations and DNA methyltransferase expression.
  • RIOK3 is linked to immune cell infiltration (fibroblasts, neutrophils, endothelial cells) and immune checkpoint markers, suggesting an immunomodulatory role.
  • RIOK3 is associated with cell-cell adhesion, protein phosphorylation, and innate immune pathways.

Conclusions:

  • RIOK3 serves as a potential independent prognostic biomarker in various malignant tumors.
  • RIOK3 demonstrates potential as an immunological biomarker for cancer immunotherapy.
  • These findings highlight RIOK3's multifaceted role in cancer, warranting further investigation for therapeutic strategies.
Keywords:
RIOK 3immune infiltrationmethylationpan-cancerprognosis

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.6K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.3K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.8K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K